Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
BCSCs
Breast cancer
Chemotherapeutics
Nanocarriers
Signaling pathways
Transporters
Tumor microenvironment
Tumor surface markers
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
12
01
2024
accepted:
27
02
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
9
4
2024
Statut:
epublish
Résumé
Despite recent advancements in the diagnosis and treatment of breast cancer (BC), patient outcomes in terms of survival, recurrence, and disease progression remain suboptimal. A significant factor contributing to these challenges is the cellular heterogeneity within BC, particularly the presence of breast cancer stem cells (BCSCs). These cells are thought to serve as the clonogenic nexus for new tumor growth, owing to their hierarchical organization within the tumor. This descriptive review focuses on the evolving strategies to target BCSCs, which have become a pivotal aspect of therapeutic development. We explore a variety of approaches, including targeting specific tumor surface markers (CD133 and CD44), transporters, heat shock proteins, and critical signaling pathways like Notch, Akt, Hedgehog, KLF4, and Wnt/β-catenin. Additionally, we discuss the modulation of the tumor microenvironment through the CXCR-12/CXCR4 axis, manipulation of pH levels, and targeting hypoxia-inducible factors, vascular endothelial growth factor, and CXCR1/2 receptors. Further, this review focuses on the roles of microRNA expression, strategies to induce apoptosis and differentiation in BCSCs, dietary interventions, dendritic cell vaccination, oncolytic viruses, nanotechnology, immunotherapy, and gene therapy. We particularly focused on studies reporting identification of BCSCs, their unique properties and the efficacy of various therapeutic modalities in targeting these cells. By dissecting these approaches, we aim to provide insights into the complex landscape of BC treatment and the potential pathways for improving patient outcomes through targeted BCSC therapies.
Identifiants
pubmed: 38592510
doi: 10.1007/s12032-024-02347-z
pii: 10.1007/s12032-024-02347-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
Organization, W.H. Preventing Cancer. 2020 [cited 2020 18-11-2020]; Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019 .
Zhou J, et al. Stem cells and cellular origins of breast cancer: updates in the rationale, controversies, and therapeutic implications. Front Oncol. 2019;9:820–820.
pubmed: 31555586
pmcid: 6722475
doi: 10.3389/fonc.2019.00820
Elbaiomy MA, et al. Clinical impact of breast cancer stem cells in metastatic breast cancer patients. J Oncol. 2020;2020:2561726.
pubmed: 32684928
pmcid: 7336231
doi: 10.1155/2020/2561726
Bianchini G, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90.
pubmed: 27184417
pmcid: 5461122
doi: 10.1038/nrclinonc.2016.66
Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–13.
pubmed: 22258609
pmcid: 3367003
doi: 10.1038/nature10762
Tudoran OM, Balacescu O, Berindan-Neagoe I. Breast cancer stem-like cells: clinical implications and therapeutic strategies. Clujul Medical. 2016;89(2):193.
pubmed: 27152067
pmcid: 4849374
Dragu DL, et al. Therapies targeting cancer stem cells: current trends and future challenges. World J Stem Cells. 2015;7(9):1185.
pubmed: 26516409
pmcid: 4620424
doi: 10.4252/wjsc.v7.i9.1185
Al-Hajj M, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.
pubmed: 12629218
pmcid: 153034
doi: 10.1073/pnas.0530291100
Shipitsin M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(3):259–73.
pubmed: 17349583
doi: 10.1016/j.ccr.2007.01.013
Kai K, et al. Breast cancer stem cells. Breast Cancer. 2010;17(2):80–5.
pubmed: 19806428
doi: 10.1007/s12282-009-0176-y
Ma X, et al. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials. 2013;34(18):4452–65.
pubmed: 23518403
doi: 10.1016/j.biomaterials.2013.02.066
Tam WL, et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013;24(3):347–64.
pubmed: 24029232
pmcid: 4001722
doi: 10.1016/j.ccr.2013.08.005
Singh JK, et al. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15(4):210.
pubmed: 24041156
pmcid: 3978717
doi: 10.1186/bcr3436
Gangopadhyay S, et al. Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer. 2013;13(1):7–15.
pubmed: 23127340
doi: 10.1016/j.clbc.2012.09.017
Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18.
pubmed: 29984391
pmcid: 6035906
doi: 10.1186/s40169-018-0198-1
Vikram R, et al. Tumorigenic and metastatic role of CD44(-/low)/CD24(-/low) cells in luminal breast cancer. Cancers. 2020;12(5):1239.
pubmed: 32423137
pmcid: 7281029
doi: 10.3390/cancers12051239
Chen K, Huang Y-H, Chen J-L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34(6):732.
pubmed: 23685952
pmcid: 3674516
doi: 10.1038/aps.2013.27
Muntimadugu E, et al. CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces. 2016;143:532–46.
pubmed: 27045981
doi: 10.1016/j.colsurfb.2016.03.075
Daquan Chen GW, Song W, Zhang Q. Novel CD44 receptor targeting multifunctional “nano-eggs” based on double pH-sensitive nanoparticles for co-delivery of curcumin and paclitaxel to cancer cells and cancer stem cells. J Nanopart Res. 2015;17:10.
Najjar MK, Manore SG, Regua AT, Lo HW. Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes (Basel). 2022;13:2065.
pubmed: 36360302
pmcid: 9691220
doi: 10.3390/genes13112065
Luksik AS, Yazigi E, Shah P, Jackson CM. CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression. Cancers (Basel). 2023;15:1414.
pubmed: 36900205
doi: 10.3390/cancers15051414
Yanze Sun XY, Wang X, et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B. 2023;13:3583–97.
pubmed: 37719370
pmcid: 10501874
doi: 10.1016/j.apsb.2023.05.023
Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2014;20(5):793–807.
pubmed: 23688078
pmcid: 6341993
doi: 10.2174/138161282005140214165212
Yue-Li Sun AP, Kumar P, Chen Z-S. Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012;31(2):51.
pubmed: 22257384
pmcid: 3777472
doi: 10.5732/cjc.011.10466
Chuthapisith S, et al. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol. 2010;19(1):27–32.
pubmed: 19251410
doi: 10.1016/j.suronc.2009.01.004
Shivhare S, Das A. Cell density modulates chemoresistance in breast cancer cells through differential expression of ABC transporters. Mol Biol Rep. 2023;50(1):215–25.
pubmed: 36319789
doi: 10.1007/s11033-022-08028-2
Cui J, et al. Targeting ABCA12-controlled ceramide homeostasis inhibits breast cancer stem cell function and chemoresistance. Sci Adv. 2023;9(48):1891.
doi: 10.1126/sciadv.adh1891
Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12(4):609–20.
pubmed: 21118092
pmcid: 3337630
doi: 10.2174/138920111795163887
Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86–103.
pubmed: 16038406
pmcid: 1176476
doi: 10.1379/CSC-99r.1
Mao L. NOTCH mutations: multiple faces in human malignancies. Cancer Prev Res (Philadelphia, Pa). 2015;8:259–61.
doi: 10.1158/1940-6207.CAPR-15-0063
Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141(2):140–9.
pubmed: 24076266
doi: 10.1016/j.pharmthera.2013.09.005
Aithal MG, Rajeswari N. Role of Notch signalling pathway in cancer and its association with DNA methylation. J Genet. 2013;92(3):667–75.
pubmed: 24371188
doi: 10.1007/s12041-013-0284-5
Harrison H, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Can Res. 2010;70(2):709–18.
doi: 10.1158/0008-5472.CAN-09-1681
Hermawan A, et al. Bioinformatics and in vitro studies reveal the importance of p53, PPARG and notch signaling pathway in inhibition of breast cancer stem cells by hesperetin. Adv Pharm Bull. 2021;11(2):351.
pubmed: 33880358
Cejuela M, Martin-Castillo B, Menendez JA, Pernas S. Metformin and breast cancer: Where are we now? Int J Mol Sci. 2022;23(5):2705.
pubmed: 35269852
pmcid: 8910543
doi: 10.3390/ijms23052705
Rossini M, Martini F, Torreggiani E, Fortini F, Aquila G, Sega FV, Patergnani S, Pinton P, Maniscalco P, Cavallesco G, Rizzo P. Metformin induces apoptosis and inhibits notch1 in malignant pleural mesothelioma cells. Front Cell Dev Biol. 2021;8:534499.
pubmed: 33537296
pmcid: 7849608
doi: 10.3389/fcell.2020.534499
Chia YH, Ma CX. Hedgehog pathway inhibitors: potential applications in breast cancer. Curr Breast Cancer Rep. 2011;3:15–23.
doi: 10.1007/s12609-010-0031-3
Tsao A-N, et al. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. Oncol Rep. 2022;47(5):1–12.
doi: 10.3892/or.2022.8316
Zhang Y, et al. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFbeta signaling pathway. Cancer Lett. 2023;560:216142.
pubmed: 36965539
doi: 10.1016/j.canlet.2023.216142
Li Y, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res. 2010;16(9):2580–90.
pubmed: 20388854
pmcid: 2862133
doi: 10.1158/1078-0432.CCR-09-2937
Moynagh PN. The NF-κB pathway. J Cell Sci. 2005;118(20):4589–92.
pubmed: 16219681
doi: 10.1242/jcs.02579
Marquardt JU, et al. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63(3):661–9.
pubmed: 25937435
pmcid: 4543531
doi: 10.1016/j.jhep.2015.04.018
Zhou J, et al. NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat. 2008;111(3):419–27.
pubmed: 17965935
doi: 10.1007/s10549-007-9798-y
Schreck R, et al. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992;175(5):1181–94.
pubmed: 1314883
doi: 10.1084/jem.175.5.1181
MacKenzie CJ, et al. Enhancement of lipopolysaccharide-stimulated JNK activity in rat aortic smooth muscle cells by pharmacological and adenovirus-mediated inhibition of inhibitory kappa B kinase signalling. Br J Pharmacol. 2003;139(5):1041–9.
pubmed: 12839879
pmcid: 1573924
doi: 10.1038/sj.bjp.0705330
Clayton S, Mousa SA. Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int. 2011;11:7.
pubmed: 21439058
pmcid: 3073868
doi: 10.1186/1475-2867-11-7
Gargini R, et al. Cancer stem cell-like phenotype and survival are coordinately regulated by Akt/FoxO/Bim pathway. Stem Cells. 2015;33(3):646–60.
pubmed: 25407338
doi: 10.1002/stem.1904
Korkaya H, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7(6):e1000121.
pubmed: 19492080
pmcid: 2683567
doi: 10.1371/journal.pbio.1000121
Ock CW, Kim GD. Dioscin decreases breast cancer stem-like cell proliferation via cell cycle arrest by modulating p38 mitogen-activated protein kinase and akt/mtor signaling pathways. J Cancer Prev. 2021;26(3):183.
pmcid: 8511578
doi: 10.15430/JCP.2021.26.3.183
Huang CC, et al. KLF4 and PCNA identify stages of tumor initiation in a conditional model of cutaneous squamous epithelial neoplasia. Cancer Biol Ther. 2005;4(12):1401–8.
pubmed: 16357510
doi: 10.4161/cbt.4.12.2355
Yu F, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011;30(18):2161.
pubmed: 21242971
pmcid: 3088782
doi: 10.1038/onc.2010.591
Orimo A, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.
pubmed: 15882617
doi: 10.1016/j.cell.2005.02.034
Welschinger R, et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2012;41(3):293–302.
pubmed: 23178377
doi: 10.1016/j.exphem.2012.11.004
Prager GW, et al. Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14–25.
pubmed: 25806151
pmcid: 4367591
Das B, et al. Quinacrine inhibits HIF-1α/VEGF-A mediated angiogenesis by disrupting the interaction between cMET and ABCG2 in patient-derived breast cancer stem cells. Phytomedicine. 2023;117:154914.
pubmed: 37321076
doi: 10.1016/j.phymed.2023.154914
Zhao J, et al. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 2015;6(1):e1600.
pubmed: 25590810
pmcid: 4669763
doi: 10.1038/cddis.2014.565
Muthoni DK, et al. Identification of 3-O-α-l-arabinosyl oleanolic acid, a triterpenoid saponin, as a new breast cancer stem cell growth inhibitor. Nat Prod Res. 2022;36(11):2923–6.
pubmed: 34058937
doi: 10.1080/14786419.2021.1933971
Zhang C, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m
pubmed: 27001847
pmcid: 4833258
doi: 10.1073/pnas.1602883113
Chen M, et al. Extracellular pH is a biomarker enabling detection of breast cancer and liver cancer using CEST MRI. Oncotarget. 2017;8(28):45759–67.
pubmed: 28501855
pmcid: 5542224
doi: 10.18632/oncotarget.17404
Wojtkowiak JW, et al. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011;8(6):2032–8.
pubmed: 21981633
pmcid: 3230683
doi: 10.1021/mp200292c
Chamie K, et al. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: data from the phase III ARISER clinical trial. Urol Oncol. 2015;33(5):204.e25-33.
pubmed: 25823535
doi: 10.1016/j.urolonc.2015.02.013
Xu Z, et al. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery. Chem Asian J. 2014;9:199–205.
pubmed: 24136878
doi: 10.1002/asia.201301030
Lee ES, et al. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Controll Release : Off J Controll Release Soc. 2008;129(3):228–36.
doi: 10.1016/j.jconrel.2008.04.024
Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem. 1996;271(34):20545–50.
pubmed: 8702798
doi: 10.1074/jbc.271.34.20545
Ginestier C, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120(2):485–97.
pubmed: 20051626
pmcid: 2810075
doi: 10.1172/JCI39397
Singh JK, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res. 2013;19(3):643–56.
pubmed: 23149820
doi: 10.1158/1078-0432.CCR-12-1063
Schott AF, et al. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer. Clin Cancer Res. 2017;23(18):5358–65.
pubmed: 28539464
pmcid: 5600824
doi: 10.1158/1078-0432.CCR-16-2748
Garg M. MicroRNAs, stem cells and cancer stem cells. World J Stem cells. 2012;4(7):62–70.
pubmed: 22993663
pmcid: 3443713
doi: 10.4252/wjsc.v4.i7.62
Yan LX, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011;13(1):R2.
pubmed: 21219636
pmcid: 3109565
doi: 10.1186/bcr2803
Shimono Y, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592–603.
pubmed: 19665978
pmcid: 2731699
doi: 10.1016/j.cell.2009.07.011
Iliopoulos D, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761–72.
pubmed: 20832727
pmcid: 2938080
doi: 10.1016/j.molcel.2010.08.013
Gong C, et al. MiR-106b expression determines the proliferation paradox of TGF-β in breast cancer cells. Oncogene. 2015;34(1):84–93.
pubmed: 24292682
doi: 10.1038/onc.2013.525
Juric et al., (2016) Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HERR ) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis. 34, 568–568.
Cao T, et al. CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway. Oncotarget. 2017;8(49):84917–27.
pubmed: 29156693
pmcid: 5689583
doi: 10.18632/oncotarget.18171
Kong L-Y, et al. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway. Oncotarget. 2017;8(9):15507–19.
pubmed: 28099945
pmcid: 5362502
doi: 10.18632/oncotarget.14662
Su X, et al. MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion. Oncol Lett. 2017;13(3):1932–8.
pubmed: 28454346
pmcid: 5403703
doi: 10.3892/ol.2017.5644
Yahya SM, et al. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene. Breast Cancer Res Treat. 2023;204(1):133–49.
pubmed: 38057687
pmcid: 10806220
doi: 10.1007/s10549-023-07170-0
Zhao Y, et al. miR-29a suppresses MCF-7 cell growth by downregulating tumor necrosis factor receptor 1. Tumor Biol. 2017;39(2):1010428317692264.
doi: 10.1177/1010428317692264
Jasim SA, et al. An in vitro investigation of the apoptosis-inducing activity of corosolic acid in breast cancer cells. Iran J Basic Med Sci. 2023;26(4):453–60.
pubmed: 37009004
pmcid: 10008398
Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344–62.
pubmed: 18267068
doi: 10.1016/j.cell.2008.01.020
Zhou J, et al. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat. 2008;111(3):419–27.
pubmed: 17965935
doi: 10.1007/s10549-007-9798-y
Gupta PB, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–59.
pubmed: 19682730
pmcid: 4892125
doi: 10.1016/j.cell.2009.06.034
Fuchs D, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–9.
pubmed: 19835841
doi: 10.1016/j.bbrc.2009.10.042
Ko D, et al. Anti-metastatic potential of pitavastatin in triple-negative breast cancer via targeting breast cancer stem-like properties and STAT3 signaling. Cancer Res. 2023;83(7):5800–5800.
doi: 10.1158/1538-7445.AM2023-5800
Nalla LV, Khairnar A. Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer. Eur J Pharmacol. 2023;943:175565.
pubmed: 36739077
doi: 10.1016/j.ejphar.2023.175565
Yan Y, et al. All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complement Altern Med. 2016;16(1):113.
pubmed: 27036550
pmcid: 4815257
doi: 10.1186/s12906-016-1088-y
Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. Tumor Biol. 2017;39(10):1010428317729933.
doi: 10.1177/1010428317729933
Yan Y, et al. All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complement Altern Med. 2016;16:113.
pubmed: 27036550
pmcid: 4815257
doi: 10.1186/s12906-016-1088-y
Patel SA, et al. Challenges in the development of future treatments for breast cancer stem cells. Breast cancer: Targ Ther. 2010;2:1.
Van Pham P, et al. Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results. Onco Targets Ther. 2016;9:4441.
pubmed: 27499638
pmcid: 4959598
doi: 10.2147/OTT.S105239
Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far. Genes Dis. 2016;3(2):114–23.
pubmed: 30123819
pmcid: 6095671
doi: 10.1016/j.gendis.2016.02.002
Korkaya H, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47(4):570–84.
pubmed: 22819326
pmcid: 3432419
doi: 10.1016/j.molcel.2012.06.014
Montales MTE, et al. Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis. 2012;33(3):652–60.
pubmed: 22219179
doi: 10.1093/carcin/bgr317
Higdon JV, et al. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007;55(3):224–36.
pubmed: 17317210
pmcid: 2737735
doi: 10.1016/j.phrs.2007.01.009
Ambrosone CB, et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004;134(5):1134–8.
pubmed: 15113959
doi: 10.1093/jn/134.5.1134
Li Y, et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16(9):2580–90.
doi: 10.1158/1078-0432.CCR-09-2937
Wang Y, et al. Differential effects of sulforaphane in regulation of angiogenesis in a co-culture model of endothelial cells and pericytes. Oncol Rep. 2017;37(5):2905–12.
pubmed: 28405689
doi: 10.3892/or.2017.5565
Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 2008;269(2):291–304.
pubmed: 18504070
pmcid: 2579766
doi: 10.1016/j.canlet.2008.04.018
Zhang M, et al. Cancer stem cells as a potential therapeutic target in breast cancer. Stem Cell Investig. 2014. https://doi.org/10.3978/j.issn.2306-9759.2014.06.01 .
doi: 10.3978/j.issn.2306-9759.2014.06.01
pubmed: 27358865
pmcid: 4923645
Berzofsky JA, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Investig. 2004;113(11):1515–25.
pubmed: 15173875
pmcid: 419494
doi: 10.1172/JCI21926
Satthaporn S, et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother. 2004;53(6):510–8.
pubmed: 14740176
doi: 10.1007/s00262-003-0485-5
Ni J, et al. Dendritic cell vaccine for the effective immunotherapy of breast cancer. Biomed Pharmacother. 2020;126:110046.
pubmed: 32145586
doi: 10.1016/j.biopha.2020.110046
Choi AH, et al. From benchtop to bedside: a review of oncolytic virotherapy. Biomedicines. 2016;4(3):18.
pubmed: 28536385
pmcid: 5344257
doi: 10.3390/biomedicines4030018
Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–70.
pubmed: 22781695
pmcid: 3888062
doi: 10.1038/nbt.2287
Rowan K. Oncolytic viruses move forward in clinical trials. JNCI J Natl Cancer Inst. 2010;102(9):590–5.
pubmed: 20421567
doi: 10.1093/jnci/djq165
Marcato P, et al. Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther. 2009;17(6):972–9.
pubmed: 19293772
pmcid: 2835173
doi: 10.1038/mt.2009.58
Wang H, et al. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med. 2012;10:167.
pubmed: 22901246
pmcid: 3478222
doi: 10.1186/1479-5876-10-167
Gomes EM, et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res. 2009;15(4):1317–25.
pubmed: 19228733
doi: 10.1158/1078-0432.CCR-08-1360
Zhang JF, et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA. 1996;93(9):4513–8.
pubmed: 8633100
pmcid: 39570
doi: 10.1073/pnas.93.9.4513
Gil M, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A. 2013;110(14):E1291–300.
pubmed: 23509246
pmcid: 3619300
doi: 10.1073/pnas.1220580110
He L, et al. Nanomedicine-mediated therapies to target breast cancer stem cells. Front Pharmacol. 2016;7:313–313.
pubmed: 27679576
pmcid: 5020043
doi: 10.3389/fphar.2016.00313
Gao Y, et al. Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotechnol Adv. 2014;32(4):761–77.
pubmed: 24211475
doi: 10.1016/j.biotechadv.2013.10.013
Estanqueiro M, et al. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631–48.
pubmed: 25591851
doi: 10.1016/j.colsurfb.2014.12.041
Shen S, Xia JX, Wang J. Nanomedicine-mediated cancer stem cell therapy. Biomaterials. 2016;74:1–18.
pubmed: 26433488
doi: 10.1016/j.biomaterials.2015.09.037
Aires A, et al. Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology. 2016;27(6):065103.
pubmed: 26754042
doi: 10.1088/0957-4484/27/6/065103
Gener P, et al. Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine. 2015;11(8):1883–92.
pubmed: 26238079
doi: 10.1016/j.nano.2015.07.009
Ganesh S, et al. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials. 2013;34(13):3489–502.
pubmed: 23410679
pmcid: 3636539
doi: 10.1016/j.biomaterials.2013.01.077
Rao W, et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano. 2015;9(6):5725–40.
pubmed: 26004286
doi: 10.1021/nn506928p
Gaio E, et al. CD44 targeting mediated by polymeric nanoparticles and combination of chlorine TPCS(2a)-PDT and docetaxel-chemotherapy for efficient killing of breast differentiated and stem cancer cells in vitro. Cancers. 2020;12(2):278.
pubmed: 31979218
pmcid: 7072409
doi: 10.3390/cancers12020278
Wang Z, et al. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomed Nanotechnol Biol Med. 2018;14(4):1441–54.
doi: 10.1016/j.nano.2018.04.004
Zhang X, et al. Dual-responsive nanoparticles based on chitosan for enhanced breast cancer therapy. Carbohydr Polym. 2019;221:84–93.
pubmed: 31227170
doi: 10.1016/j.carbpol.2019.05.081
Jeong K, et al. Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy. Cancer Lett. 2016;374(1):31–43.
pubmed: 26854717
doi: 10.1016/j.canlet.2016.01.050
Zhang L, et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials. 2012;33(2):565–82.
pubmed: 21983136
doi: 10.1016/j.biomaterials.2011.09.055
Yu LY, et al. Glucose transporter 1-mediated transcytosis of glucosamine-labeled liposomal ceramide targets hypoxia niches and cancer stem cells to enhance therapeutic efficacy. ACS Nano. 2023;17(14):13158–75.
pubmed: 37436002
doi: 10.1021/acsnano.2c12123
Nguyen VD, et al. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo. Colloids Surf B Biointerfaces. 2019;173:539–48.
pubmed: 30343218
doi: 10.1016/j.colsurfb.2018.10.013
Chiani M, et al. Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin. Artif Cells Nanomed Biotechnol. 2018;46(4):757–63.
pubmed: 28643525
doi: 10.1080/21691401.2017.1337029
Kushwah V, et al. Improved antitumor efficacy and reduced toxicity of docetaxel using anacardic acid functionalized stealth liposomes. Colloids Surf B Biointerfaces. 2018;172:213–23.
pubmed: 30172202
doi: 10.1016/j.colsurfb.2018.08.047
Hong S, et al. Aptamer-integrated α-Gal liposomes as bispecific agents to trigger immune response for killing tumor cells. J Biomed Mater Res A. 2019;107(6):1176–83.
pubmed: 30650243
doi: 10.1002/jbm.a.36609
Kim YJ, et al. Co-eradication of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment. Mol Pharm. 2015;12(8):2811–22.
pubmed: 26098197
doi: 10.1021/mp500754r
Rana MS, et al. A new liposomal nanocarrier for co-delivery of gedunin and p-glycoprotein siRNA to target breast cancer stem cells. Nat Prod Res. 2022;36(24):6389–92.
pubmed: 35084278
doi: 10.1080/14786419.2022.2032048
Ahmad A, et al. Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model. Mol Pharm. 2016;13(3):1081–8.
pubmed: 26832839
doi: 10.1021/acs.molpharmaceut.5b00900
Zhang Y, et al. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials. 2012;33(2):679–91.
pubmed: 22019123
doi: 10.1016/j.biomaterials.2011.09.072
Ke XY, et al. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials. 2014;35(3):1096–108.
pubmed: 24183698
doi: 10.1016/j.biomaterials.2013.10.049
Zhang J, et al. Effective treatment of drug resistant recurrent breast tumors harboring cancer stem-like cells by staurosporine/epirubicin co-loaded polymeric micelles. J Control Release. 2017;264:127–35.
pubmed: 28842317
doi: 10.1016/j.jconrel.2017.08.025
Xiang J, et al. Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy. Sci China Life Sci. 2018;61(4):436–47.
pubmed: 29572777
doi: 10.1007/s11427-017-9274-9
Lecot et al., Glucosylated polymeric micelles actively target a breast cancer model. n/a(n/a), 2000010
Amreddy N, et al. Recent advances in nanoparticle-based cancer drug and gene delivery. Adv Cancer Res. 2018;137:115–70.
pubmed: 29405974
doi: 10.1016/bs.acr.2017.11.003
Sun R, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials. 2015;37:405–14.
pubmed: 25453968
doi: 10.1016/j.biomaterials.2014.10.018
de Sousa Marcial SP, Carneiro G, Leite EA. Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment. J Nanoparticle Res. 2017;19(10):340.
doi: 10.1007/s11051-017-4042-0
Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine. 2011;7(6):834–40.
pubmed: 21371568
doi: 10.1016/j.nano.2011.02.001
Şalva E, et al. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF. Int J Pharm. 2015;478(1):147–54.
pubmed: 25445537
doi: 10.1016/j.ijpharm.2014.10.065
Li SY, et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J Control Release. 2015;205:7–14.
pubmed: 25445694
doi: 10.1016/j.jconrel.2014.11.011
Jin G, et al. Theranostics of triple-negative breast cancer based on conjugated polymer nanoparticles. ACS Appl Mater Interfaces. 2018;10(13):10634–46.
pubmed: 29323875
doi: 10.1021/acsami.7b14603
Shen S, et al. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. J Control Release. 2015;208:14–24.
pubmed: 25575864
doi: 10.1016/j.jconrel.2014.12.043
Sun R, et al. Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. Biomaterials. 2016;103:44–55.
pubmed: 27376558
doi: 10.1016/j.biomaterials.2016.06.038
Gao J, et al. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomed. 2019;14:9199–216.
doi: 10.2147/IJN.S230376
Jeon M, et al. Paclitaxel-loaded iron oxide nanoparticles for targeted breast cancer therapy. Adv Ther. 2019;2(12):1900081.
doi: 10.1002/adtp.201900081
Tran T, et al. Synergistic therapeutic strategy of dual drug-loaded lipid polymer hybrid nanoparticles for breast cancer treatment. Indian J Pharm Sci. 2019;81:474–82.
doi: 10.36468/pharmaceutical-sciences.532
Esnaashari SS, et al. A combinational approach towards treatment of breast cancer: an analysis of noscapine-loaded polymeric nanoparticles and doxorubicin. AAPS PharmSciTech. 2020;21(5):166.
pubmed: 32504144
doi: 10.1208/s12249-020-01710-3
Sulaiman A, et al. Co-targeting bulk tumor and CSCs in clinically translatable tnbc patient-derived xenografts via combination nanotherapy. Mol Cancer Ther. 2019;18(10):1755.
pubmed: 31308079
doi: 10.1158/1535-7163.MCT-18-0873
Zhang N, et al. Loading lovastatin into camptothecin-floxuridine conjugate nanocapsules for enhancing anti-metastatic efficacy of cocktail chemotherapy on triple-negative breast cancer. ACS Appl Mater Interfaces. 2018;10(35):29385–97.
pubmed: 30096224
doi: 10.1021/acsami.8b11723
Liang DS, et al. Vitamin E-based redox-sensitive salinomycin prodrug-nanosystem with paclitaxel loaded for cancer targeted and combined chemotherapy. Colloids Surf B Biointerfaces. 2018;172:506–16.
pubmed: 30212688
doi: 10.1016/j.colsurfb.2018.08.063
Tran TA, et al. Inhibitory effect of zinc sulfide nanoparticles towards breast cancer stem cell migration and invasion. J Biomed Nanotechnol. 2016;12(2):329–36.
pubmed: 27305766
doi: 10.1166/jbn.2016.2187
Dash SR, et al. Near-infrared enhances antiangiogenic potentiality of quinacrine-gold hybrid nanoparticles in breast cancer stem cells via deregulation of HSP-70/TGF-beta. Nanomedicine (Lond). 2023;18(1):19–33.
pubmed: 36916388
doi: 10.2217/nnm-2022-0243
Wu K, et al. An iron oxyhydroxide-based nanosystem sensitizes ferroptosis by a “Three-Pronged” strategy in breast cancer stem cells. Acta Biomater. 2023;160:281–96.
pubmed: 36822484
doi: 10.1016/j.actbio.2023.02.015
Sarika PR, Nirmala RJ. Curcumin loaded gum arabic aldehyde-gelatin nanogels for breast cancer therapy. Mater Sci Eng, C. 2016;65:331–7.
doi: 10.1016/j.msec.2016.04.044
Guo H, et al. Chitosan-based nanogel enhances chemotherapeutic efficacy of 10-hydroxycamptothecin against human breast cancer cells. Int J Polym Sci. 2019;2019:1914976.
doi: 10.1155/2019/1914976
Gülçür E, et al. Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. Drug Deliv Transl Res. 2013;3(6):562–74. https://doi.org/10.1007/s13346-013-0167-6 .
doi: 10.1007/s13346-013-0167-6
Dian L-H, et al. Fabrication of paclitaxel hybrid nanomicelles to treat resistant breast cancer via oral administration. Int J Nanomed. 2018;13:719–31.
doi: 10.2147/IJN.S150140
Gong Z, et al. Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer. Signal Transduct Target Ther. 2020;5(1):12.
pubmed: 32296050
pmcid: 7005157
doi: 10.1038/s41392-019-0104-3
Farhadi S, et al. Exosomal delivery of 7SK long non-coding RNA suppresses viability, proliferation, aggressiveness and tumorigenicity in triple negative breast cancer cells. Life Sci. 2023;322:121646.
pubmed: 37011870
doi: 10.1016/j.lfs.2023.121646
Ohno S-I, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21(1):185–91.
pubmed: 23032975
doi: 10.1038/mt.2012.180
Yang M, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer. 2011;10(1):117.
pubmed: 21939504
pmcid: 3190352
doi: 10.1186/1476-4598-10-117
Mina LA, et al. Immunotherapy for the treatment of breast cancer: emerging new data. Breast cancer (Dove Medical Press). 2019;11:321–8.
pubmed: 32099454
Yang M, et al. Mesothelin-targeted CAR-NK cells derived from induced pluripotent stem cells have a high efficacy in killing triple-negative breast cancer cells as shown in several preclinical models. J Immunother. 2023;46(8):285–94.
pubmed: 37584622
doi: 10.1097/CJI.0000000000000483
Nanda R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7.
pubmed: 27138582
pmcid: 6816000
doi: 10.1200/JCO.2015.64.8931
Dirix LY, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167(3):671–86.
pubmed: 29063313
doi: 10.1007/s10549-017-4537-5
Schmid P, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21.
pubmed: 30345906
doi: 10.1056/NEJMoa1809615
Adams S, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404.
pubmed: 30475950
doi: 10.1093/annonc/mdy517
Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810–21.
pubmed: 32101663
doi: 10.1056/NEJMoa1910549
Lang J-Y, et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 2011;20(3):341–56.
pubmed: 21907925
pmcid: 3172580
doi: 10.1016/j.ccr.2011.07.017
Thapa B, et al. Breathing new life into TRAIL for breast cancer therapy: co-delivery of pTRAIL and complementary siRNAs using lipopolymers. Hum Gene Ther. 2019;30(12):1531–46.
pubmed: 31547718
doi: 10.1089/hum.2019.096
Kretzmann JA, et al. Tumor suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. Chem Sci. 2019;10(33):7718–27.
pubmed: 31588320
pmcid: 6761875
doi: 10.1039/C9SC01432B
Moradian C, Rahbarizadeh F. Targeted toxin gene therapy of breast cancer stem cells using CXCR1 Promoter and bFGF 5’UTR. Onco Targets Ther. 2019;12:8809–20.
pubmed: 31695436
pmcid: 6821057
doi: 10.2147/OTT.S221223
Zuo ZQ, et al. Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-beta signaling pathway inhibition. Biomaterials. 2016;82:48–59.
pubmed: 26751819
doi: 10.1016/j.biomaterials.2015.12.014
Agency FD. New Drug Approvals for 2019. 2019 [cited 2020 18-11-2020]; Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019 .
Agency FD, Novel drug approvals for 2020. 2020 [cited 2020 18-11-2020]; Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020 .